A carregar...
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30(+) Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with brentuximab vedotin used alone to treat 240 refractory/relapsed Hodgkin lymphoma...
Na minha lista:
| Publicado no: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Ferrata Storti Foundation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004383/ https://ncbi.nlm.nih.gov/pubmed/26768687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.134213 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|